OncoSil Medical (ASX:OSL) – on its mission to combat pancreatic cancer – has now dosed the first two patients in Austria with the use of the OncoSilTM device.
In early trade Oncosil shares catapulted as much as 30 per cent after announcing that Universitätsklinikum St. Pölten – renowned for its advanced medical treatments – had proven an ideal location for the administration of OncoSilTM treatments. The completion of treatments at the institution had emphasised the efficacy and potential of the OncoSilTM device in combating pancreatic cancer, the company said.
This treatment process had signified the company’s commitment to providing cutting-edge medical solutions to patients not just in Austria, but globally.
With the assistance of distributor partner THP Medical Products Vertriebs GmbH, OncoSil has now successfully penetrated key European countries, including Spain, Italy, Greece, and now Austria.
With commercial treatments now completed in these four European countries, OncoSil’s presence in the region continues to grow. This list is expected to expand further in the coming month, with other European countries, including the UK, Portugal and Germany, having commenced training on usage of the device.
“These treatments yet again demonstrate our ability to deliver tangible evidence that the OncoSilTM device is gaining traction as a treatment option for patients with locally advanced pancreatic cancer,” OncoSil Medical CEO & Managing Director Nigel Lange, said.
OSL has been trading at 0.6 cents.